A new antiarrhythmic drug, prolecofen (class Ic), was used in 74 patients with various forms of coronary heart disease, involving heart rhythm disorders. The drug's clinical efficiency and effects on platelet activity, lipid peroxidation, blood prostacyclin, thromboxane, cAMP and cGMP were assessed. Prolecofen is shown to be an effective agent for the treatment of ventricular and supraventricular arrhythmias in coronary patients. It contributes to the inhibition of platelet activity, a drop of cAMP and cGMP levels and a rise of the cAMP/cGMP ratio.
Download Full PDF Version (Non-Commercial Use)